On July 27, 2020 NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, reported receipt of IND clearance from the US Federal Drug Administration (FDA) to evaluate NT-I7 (efineptakin alfa), the only clinical-stage long-acting human IL-7, in a Window-of-Opportunity trial for patients with locally recurrent squamous cell carcinoma of head and neck (SCCHN) undergoing salvage surgery (Press release, NeoImmuneTech, JUL 27, 2020, View Source [SID1234562412]). The investigator-initiated trial is being conducted by Hyunseok Kang, M.D., Associate Professor of Clinical Medicine at the University of California, San Francisco.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Over half a million people worldwide are diagnosed with SCCHN every year, making it the sixth most common cancer in the world. Even with intense treatment, about 20-40% of patients experience disease progression or recurrence and would receive salvage surgery as standard of care for locally recurrent disease. Since the majority of these patients had received prior chemoradiotherapy, these patients typically suffer critical shortage of lymphocytes, known as lymphopenia, which is associated with poor prognosis. NT-I7 has demonstrated clinically to help overcome lymphopenia in cancer patients by expanding lymphocyte counts in the peripheral blood as well as in the tumor microenvironment.

"SCCHN has a high rate of recurrence, and salvage surgeries attempted for locally recurrent disease have not been very successful," said Dr. Kang. "Since the majority of these patients received prior chemoradiation, many suffer from treatment-related lymphopenia, which likely results in poor response to systemic anticancer therapy. We hypothesize that by expanding lymphocytes and reverting lymphopenia with NT-I7, we can enhance the efficacy of immune checkpoint inhibitors which are already approved in SCCHN."

"NT-I7’s promising ability to overcome lymphopenia and its excellent safety profile make it especially well-suited as a combination partner with other cancer therapeutics," said NgocDiep Le, M.D., Ph.D., Executive Vice President and Chief Medical Officer of NeoImmuneTech. "The data generated from this study can be used as a proof of concept for how NT-I7 can augment immune checkpoint inhibitors and help to develop interventional studies using NT-I7 based combinations. We believe that our immune enhancer, NT-I7, has the potential to provide new and improved treatment options for patients with this devastating disease."

About NT-I7

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed for oncologic and immunologic indications, in which T-cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T-cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.